Clinical Research Professionals Experience

1. A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One-Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn’s disease

2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

3. A Phase 3, 52 Week, Randomized, Double-Blind, 3-arm Parallel Group Study, comparing the Efficacy, Safety and Tolerability of the fixed Dose triple combination FF/UMEC/VI With the fixed Dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer’s disease receiving acetylcholinesterase inhibitors and/or memantine

5. A Phase 3, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisifolia) Sublingual ImmunoTherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma

6. A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA – Intervention Trial) Investigational Product: AMR101 (icosapent ethyl [ethyl-EPA])

7. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSD) (With or Without Decreased Arousal)

8. A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

9. A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn’s Disease Receiving Oral RPC1063 as Induction Therapy

10. Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer’s Disease Dementia
11. A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in **Prodromal Alzheimer's Disease**

12. Multicenter, Prospective, Randomized Study Comparing the Diagnostic Yield of **Colon Capsule Endoscopy versus Computed Tomographic Colonography in a Screening Population** (the TOPAZ study)

13. Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor Methotrexate Regimen in Subjects with **Moderate to Severe Rheumatoid Arthritis**

14. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with **Active Rheumatoid Arthritis** on Background Therapy with Methotrexate

15. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with **Early Alzheimer's Disease (EAD)** including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of E2609.

16. A Phase 2, 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, and Efficacy of SM04690 for the Treatment of **Moderately to Severely Symptomatic Osteoarthritis Subjects**

17. A Phase 2, Placebo-Controlled, Efficacy, Safety and PK/PD Study Once-Weekly, Subcutaneous LY3298176 Compared with Placebo and Dulaglutide in Patients with **Type 2 Diabetes Mellitus**

18. A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] for the treatment of **neurobehavioral disinhibition, including aggression, agitation, and irritability**, in patients with traumatic brain injury [TBI]

19. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in **Mild Alzheimer's Disease Dementia** (The DAYBREAK Study)

20. Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon In Patients with **Mild Alzheimer's Disease**

21. A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 versus Placebo in Patients with **Type 2 Diabetes Mellitus**

22. Effect of LY3154207 on Cognition in **Mild-to-Moderate Parkinson's Disease Dementia (PDD)** (The PRESENCE Study)

23. A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with **Type 2 Diabetes Mellitus** (AWARD-11: Assessment of Weekly Administration of LY2189265 in Diabetes-11)
24. **A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 MG and 100 MG of SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride**

25. **Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease, PERISCOPE-ALZ**

26. **A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors**

27. **Patient Impact Priorities in Parkinson's Study (PIPPS), Survey Study**

28. **Phase 3, A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-related Psychosis**

29. **A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis, ECO-RESET**

30. **Phase 2/3, A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of Alzheimer's Type, ADVANCE Study**

31. **Phase 3, Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk, SURPASS-4 Study**

32. **A Phase 3, Randomized Observer-Blinded Study to Evaluate the Immunogenicity, Safety, and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age or Older, B5091019**

33. **A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis, Falcon 1**

34. **A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis, Falcon 2**

35. **A Randomized, Phase 3, Open-label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes, SURPASS-3**

36. **A Randomized, Phase 3, Double-blind, Placebo-Controlled Trial Comparing the Effect of Three Tirzepatide Doses with Placebo on Glycemic Control in Patients with Type 2 Diabetes Insufficiently Controlled with Diet and Exercise, SURPASS-1**
37. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention, BHV3000-305

38. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis, AURORA, 3152-301-002

39. Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis, FLUTE-2, SP-1011-008

40. Phase 3, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis, VP-VLY-686-3301, NCT04028492

41. Phase IIb, A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis, ELIVATE, CLJN452D12201C, NCT04065841

42. Clinical Validation of an Optimized Multi-Target Stool DNA (mt-sDNA 2.0) test for Colorectal Cancer Screening, Blue-C, #2019-01/2019-01B

43. Phase 3, A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release table) on slowing progression of mild cognitive impairment due to Alzheimer's disease, AGB101 MCD

44. Non Treatment, Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode, ECLIPSE/02-GI-002

45. A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against Covid-19 Healthy Adults, Protocol C4591001, NCT 04368728

Clinical Research Professional Team Experience

1. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Gilead Sciences, Inc.), 2016 to 2017

2. A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) NSCLC with MET exon 14 (METex14) skipping alterations- VISION (EMO Serono Research & Development Institute, Inc), 2016 to 2017

3. Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) - ADVANCE (Spectrum Pharmaceuticals, Inc.), 2016 to 2017

5. A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (Bl 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures - RE-VERSE­ AD (Boehringer-Ingelheim), 2015 to 2016

6. The Angel Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects (BiO2 Medical, Inc), 2014 to 2016

7. SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH­ SYMPACT (Actelion Pharmaceuticals US, Inc), 2013-2015

8. Evaluating the Use of Polymyx.in B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock - EUPHRATES (Spectral Diagnostics), 2013 to 2016

9. Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the treatment of Critical Limb Ischemia due to Peripheral Arterial Occlusive Disease - HARVEST (Harvest Technologies Corp.), 2013-2015

10. An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia, Protocol 019-02-03-CR, Phase III

11. A 4-Week Randomized, Multi-Center, Double-Blind, Placebo- and Active-controlled, Parallel-group, Forced-titration Phase IIB Study Comparing Efficacy and Safety of Ascending Doses of Cg5503 Prolonged Release Up to 233mg BID and Oxycodone Prolonged Release Up to 20 mg BID to Placebo in Subjects with Moderate to Severe Chronic Pain due to Osteoarthritis of the Knee, Protocol R331333-PAI-2001, Phase IIB

12. A 52-Week International, Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100mg and Celecoxib 200mg QD in Patients with Primary Osteoarthritis of Hip, Knee, Hand or Spine, Protocol COX189A2369, Phase III

13. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Trial of Rosuvastatin 20mg in the Primary Prevention of Cardiovascular Events Amount Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein, Protocol 4522US/0011, Phase III

14. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR II0322 in Patients with Type 2 Diabetes, Who are Either Receiving No Current Treatment or Currently Treated with Diet and Exercise a Sulfonylurea, Metformin, or a Combination of a Sulfonylurea and Metformin, Protocol SYR-322-003, Phase II
15. A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects, Protocol 1535-RESI-07, Phase II

16. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg) Multicenter study of Long-Term Glycemic Control With Rimonabant in Treatment-Naive Patients With Type 2 Diabetes, Protocol EFC5825, Phase IIIb

17. A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 years) of Treatment with LAF237 50 mg bid to Glimepiride up to 8 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, Protocol LAF237A2308, Phase III

18. A Multicenter, Randomized, Double-Blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients with Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia, Protocol 077-00, Phase III

19. A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Pregabalin Twice Daily in Patients with Fibromyalgia, Protocol A0081077, Phase III

20. A Three-Month, Open-Label, Safety Trial of Pregabalin in Patients with Fibromyalgia, Protocol A0081078, Phase III


22. Duloxetine 601l20 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome, Protocol F1J-MC-HMEF.

23. The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control, Protocol F3Z-US-IOOV, Phase IV

24. Effect on weight loss of Exenatide versus Placebo in subjects with Type 2 Diabetes participating in a Lifestyle Modification Program, Protocol H80-US-GWBM

25. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Diabetes, Protocol SYR-322-SULF-007, Phase III

26. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes, Protocol SYR-322-MET-008, Phase III

27. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety ofSYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabetes, Protocol SYR-322-TZD-009, Phase III
28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYRIIO322 (SYR-322) When Used in Combination with Insulin in Subjects with Type 2 Diabetes, Protocol SYR-322-INS-011, Phase III

29. A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYRI10322 (SYR-322) in Subjects with Type 2 Diabetes, Protocol SYR-322-OLE-012, Phase III

30. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors, Protocol EFC5826, Phase III


32. Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome, Protocol FIJ-MC-HMCI, Phase III


34. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Safety and Efficacy of BMS-477118 in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone. Protocol CV168-014, Phase III

35. A Double-Blind, Randomized Placebo-Controlled Trial of the Time to Onset of Meaningful Pain Relief in Subjects with Postherpetic Neuralgia (PHN) Treated with Pregabalin (150-600 MG/Day Flexible Optimized Dose or 300 MG/Day Fixed Dose of Placebo, Protocol A0081004, Phase IIIb

36. Pulmonary Outcomes within a 2-Year Period in Subjects with Diabetes Mellitus Treated with Technosphrere®/Insulin or Usual Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control, Protocol MKC-TI-030, Phase IIIa

37. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5 mg Once Daily and 0.5 mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain, Protocol SB767905/013, Phase III

38. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5 mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain, Protocol SB767905/014, Phase III
39. A 28-week, Multicenter, Randomized, Active Controlled, Parallel Group Study to Evaluate the Effects of Diovan HCT (160/12.5 mg) in Comparison with Hydrochlorothiazide 25 mg) Monotherapy, for the Treatment of Patients with Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy, Protocol VAH631BUS04, Phase III

40. An Eight Week, Randomized, Double-Blind, Parallel-Group, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Triple Combination of Aliskiren/ Valsartan/ HCTZ (150/160/25mg and 300/320/25 mg), Compared to the Double Combinations of Aliskiren/HCTZ (150/25 mg or 300/25 mg) or Valsartan/HCTZ (160/25 mg or 320/25 mg) in Patients with Essential Hypertension Not Adequately Responsive to HCTZ 25mg, Protocol CSPP100A2331, Phase III

41. A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus, Protocol 047-00. Phase III

42. A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability, and Efficacy of AVE0010 in Metformin-Treated Subject with Type 2 Diabetes Mellitus, Protocol DRI6012

43. Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP-529,414)/Atorvastatin Administered Orally, Once Daily (QD) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia, Protocol A5091025

44. A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Monotherapy in Subjects with Mixed Dyslipidemia, Protocol M05-749 & MOS-78

45. A double-blind, randomized, placebo-controlled factorial study to evaluate the efficacy and safety of TAK-475 and simvastatin alone and in combination in subjects with primary hypercholesterolemia, Protocol 01-05-TL-745-020. Phase III.


48. A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability, and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus, Protocol AVE0010/2002/DR16012
49. A Randomized, Double-Blind, Placebo-Controlled, Parallel-group, multicenter Study Evaluating the Efficacy and Safety of Three Doses of AVE1625 in Abdominally Obese Patients with Atherogenic Dyslipidemia, Protocol AVE1625/DRI6412

50. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy, Protocol: A0081071


52. To assess the efficacy of duloxetine compared with placebo on the reduction of chronic low back pain, in a 12-week, double-blind, randomized study. Protocol F1J-MC-HMEO

53. A Multicenter, Double-Blind, Randomized Parallel Group Study to Demonstrate The Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd as Add-on to Metformin 500 mg bid Compared to Metformin up to 1000 mg bid in Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg bid Monotherapy, Protocol LAF237A23104, Phase III

54. A Multicenter, Prospective, Non-Randomized Clinical Trial Using an Investigational Assay to Test the Validity of the 3q Biomarker for the Detection of Dysplastic Cervical Lesions in Routinely Collected Cytological Specimens and the Establishment of individualized Progression Risk Profiles, Protocol NEO-003

55. Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker, Protocol SQNM-T21-202

56. A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF), Protocol 1245.110 Phase III

57. A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF), Protocol 1245.121, Phase III

58. A Multicenter, double-blind, placebo-controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes mellitus, Protocol D513BC00001, Phase IIIb

59. A Phase IV prospective, randomized, parallel group, double bind trial in patients with evidence of device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke, treatment with apixaban compared with aspirin will reduce the risk of composite of stroke and systemic embolism, Protocol #20150286

60. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical
diagnosis of diabetic kidney disease in addition to standard of care, Protocol BAY 94-8862/16244 & 17530

61. Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction, Protocol CLCZ696BUS05

62. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency, Protocol 1VIT15043

63. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome, Protocol EFC11570

64. A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA), Protocol MK-1242-001-01

65. A Multicenter Registry Heart Failure Optimization Study, Prospective observational study to observe the rate of recovery of ventricular function (EF>35%) between 90 and 180 days in newly diagnosed Heart Failure patients, Protocol 90D0109

66. A Phase III randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS – Cardiovascular OutcoMes for People using Anticoagulation Strategies) Rivaroxaban for the prevention of major cardiovascular events in CAD or PAD, Protocol BAY 59-7939/15786